Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015 (2015), Article ID 938475, 19 pages
http://dx.doi.org/10.1155/2015/938475
Review Article

Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy

Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, 47921 Rimini, Italy

Received 25 September 2014; Accepted 2 December 2014

Academic Editor: David Vauzour

Copyright © 2015 Eleonora Turrini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, E. Ward, O. Brawley, and A. Jemal, “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” CA Cancer Journal for Clinicians, vol. 61, no. 4, pp. 212–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Boeing, A. Bechthold, A. Bub et al., “Critical review: vegetables and fruit in the prevention of chronic diseases,” European Journal of Nutrition, vol. 51, no. 6, pp. 637–663, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. N. P. Seeram, L. S. Adams, S. M. Henning et al., “In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice,” Journal of Nutritional Biochemistry, vol. 16, no. 6, pp. 360–367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. E. P. Lansky and R. A. Newman, “Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer,” Journal of Ethnopharmacology, vol. 109, no. 2, pp. 177–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Gu, M. A. Kelm, J. F. Hammerstone et al., “Concentrations of proanthocyanidins in common foods and estimations of normal consumption,” Journal of Nutrition, vol. 134, no. 3, pp. 613–617, 2004. View at Google Scholar · View at Scopus
  6. A. Faria and C. Calhau, “The bioactivity of pomegranate: impact on health and disease,” Critical Reviews in Food Science and Nutrition, vol. 51, no. 7, pp. 626–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Seeram, R. Lee, M. Hardy, and D. Heber, “Rapid large scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry,” Separation and Purification Technology, vol. 41, no. 1, pp. 49–55, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. I. F. F. Benzie and S. Wachtel-Galor, Herbal Medicine: Biomolecular and Clinical Aspects, CRC Press, Boca Raton, Fla, USA, 2nd edition, 2011.
  9. M. I. Gil, F. A. Tomas-Barberan, B. Hess-Pierce, D. M. Holcroft, and A. A. Kader, “Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing,” Journal of Agricultural and Food Chemistry, vol. 48, no. 10, pp. 4581–4589, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Cerdá, R. Llorach, J. J. Cerón, J. C. Espín, and F. A. Tomás-Barberán, “Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice,” European Journal of Nutrition, vol. 42, no. 1, pp. 18–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Cerdá, J. C. Espín, S. Parra, P. Martínez, and F. A. Tomás-Barberán, “The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans,” European Journal of Nutrition, vol. 43, no. 4, pp. 205–220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Espín, R. González-Barrio, B. Cerdá, C. López-Bote, A. I. Rey, and F. A. Tomás-Barberán, “Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans,” Journal of Agricultural and Food Chemistry, vol. 55, no. 25, pp. 10476–10485, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Larrosa, F. A. Tomás-Barberán, and J. C. Espín, “The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway,” Journal of Nutritional Biochemistry, vol. 17, no. 9, pp. 611–625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. N. P. Seeram, W. J. Aronson, Y. Zhang et al., “Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland,” Journal of Agricultural and Food Chemistry, vol. 55, no. 19, pp. 7732–7737, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. P. Seeram, R. Lee, and D. Heber, “Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice,” Clinica Chimica Acta, vol. 348, no. 1-2, pp. 63–68, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. S. U. Mertens-Talcott, P. Jilma-Stohlawetz, J. Rios, L. Hingorani, and H. Derendorf, “Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum L.) polyphenols after ingestion of a standardized extract in healthy human volunteers,” Journal of Agricultural and Food Chemistry, vol. 54, no. 23, pp. 8956–8961, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Aqil, R. Munagala, M. V. Vadhanam et al., “Anti-proliferative activity and protection against oxidative DNA damage by punicalagin isolated from pomegranate husk,” Food Research International, vol. 49, no. 1, pp. 345–353, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. P. Kulkarni, H. S. Mahal, S. Kapoor, and S. M. Aradhya, “In vitro studies on the binding, antioxidant, and cytotoxic actions of punicalagin,” Journal of Agricultural and Food Chemistry, vol. 55, no. 4, pp. 1491–1500, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Noda, T. Kaneyuki, A. Mori, and L. Packer, “Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin,” Journal of Agricultural and Food Chemistry, vol. 50, no. 1, pp. 166–171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. M. V. Dassprakash, R. Arun, S. K. Abraham, and K. Premkumar, “In vitro and in vivo evaluation of antioxidant and antigenotoxic potential of Punica granatum leaf extract,” Pharmaceutical Biology, vol. 50, no. 12, pp. 1523–1530, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Zahin, I. Ahmad, R. C. Gupta, and F. Aqil, “Punicalagin and ellagic acid demonstrate antimutagenic activity and inhibition of benzo[a]pyrene induced DNA adducts,” BioMed Research International, vol. 2014, Article ID 467465, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Aqil, M. V. Vadhanam, and R. C. Gupta, “Enhanced activity of punicalagin delivered via polymeric implants against benzo[a]pyrene-induced DNA adducts,” Mutation Research—Genetic Toxicology and Environmental Mutagenesis, vol. 743, no. 1-2, pp. 59–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Sayer, H. Yagi, A. W. Wood, A. H. Conney, and D. M. Jerina, “Extremely facile reaction between the ultimate carcinogen benzo[a]pyrene-7,8-diol 9,10-epoxide and ellagic acid,” Journal of the American Chemical Society, vol. 104, no. 20, pp. 5562–5564, 1982. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Pohl, A. Hombach, and W. Kruis, “Chronic inflammatory bowel disease and cancer,” Hepato-Gastroenterology, vol. 47, no. 31, pp. 57–70, 2000. View at Google Scholar · View at Scopus
  25. L. S. Adams, N. P. Seeram, B. B. Aggarwal, Y. Takada, D. Sand, and D. Heber, “Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells,” Journal of Agricultural and Food Chemistry, vol. 54, no. 3, pp. 980–985, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Banerjee, H. Kim, S. Talcott, and S. Mertens-Talcott, “Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126/VCAM-1 and miR-126/PI3K/ AKT/mTOR,” Carcinogenesis, vol. 34, no. 12, pp. 2814–2822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Marín, R. M. Giner, J.-L. Ríos, and M. C. Recio, “Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis,” Journal of Ethnopharmacology, vol. 150, no. 3, pp. 925–934, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Mehta and E. P. Lansky, “Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture,” European Journal of Cancer Prevention, vol. 13, no. 4, pp. 345–348, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Dai, V. Nair, M. Khan, and H. P. Ciolino, “Pomegranate extract inhibits the proliferation and viability of MMTV-Wnt-1 mouse mammary cancer stem cells in vitro,” Oncology Reports, vol. 24, no. 4, pp. 1087–1091, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Smith, C. Salcido, M. Carlson, S. Hursting, and L. Varticovski, “Wnt-1 mammary tumors are enriched in CD44+/CD24- cells with cancer stem cell characteristics,” AACR Meeting Abstracts, vol. 2009, article 3087, 2009. View at Google Scholar
  31. K. M. Cadigan and R. Nusse, “Wnt signaling: a common theme in animal development,” Genes and Development, vol. 11, no. 24, pp. 3286–3305, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Barker and H. Clevers, “Mining the Wnt pathway for cancer therapeutics,” Nature Reviews Drug Discovery, vol. 5, no. 12, pp. 997–1014, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. N. A. H. Sadik and O. G. Shaker, “Inhibitory effect of a standardized pomegranate fruit extract on wnt signalling in 1, 2-dimethylhydrazine induced rat colon carcinogenesis,” Digestive Diseases and Sciences, vol. 58, no. 9, pp. 2507–2517, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. V. Selma, J. C. Espín, and F. A. Tomás-Barberán, “Interaction between phenolics and gut microbiota: role in human health,” Journal of Agricultural and Food Chemistry, vol. 57, no. 15, pp. 6485–6501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Sharma, L. Li, J. Celver, C. Killian, A. Kovoor, and N. P. Seeram, “Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling,” Journal of Agricultural and Food Chemistry, vol. 58, no. 7, pp. 3965–3969, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. A. Nunez-Sanchez, R. Garcia-Villalba, T. Monedero-Saiz et al., “Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients,” Molecular Nutrition & Food Research, vol. 58, no. 6, pp. 1199–1211, 2014. View at Publisher · View at Google Scholar
  37. M. I. Waly, A. Ali, N. Guizani, A. S. Al-Rawahi, S. A. Farooq, and M. S. Rahman, “Pomegranate (Punica granatum) peel extract efficacy as a dietary antioxidant against azoxymethane-induced colon cancer in rat,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 8, pp. 4051–4055, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. I. Waly, A. S. Al-Rawahi, M. Al Riyami et al., “Amelioration of azoxymethane induced-carcinogenesis by reducing oxidative stress in rat colon by natural extracts,” BMC Complementary and Alternative Medicine, vol. 14, article 60, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Bishayee, D. Bhatia, R. J. Thoppil, A. S. Darvesh, E. Nevo, and E. P. Lansky, “Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms,” Carcinogenesis, vol. 32, no. 6, pp. 888–896, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Bishayee, R. J. Thoppil, A. S. Darvesh, V. Ohanyan, J. G. Meszaros, and D. Bhatia, “Pomegranate phytoconstituents blunt the inflammatory cascade in a chemically induced rodent model of hepatocellular carcinogenesis,” Journal of Nutritional Biochemistry, vol. 24, no. 1, pp. 178–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Faria, R. Monteiro, I. Azevedo, and C. Calhau, “Pomegranate juice effects on cytochrome p450s expression: in vivo studies,” Journal of Medicinal Food, vol. 10, no. 4, pp. 643–649, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Farkas, L. E. Oleson, Y. Zhao et al., “Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice,” Journal of Clinical Pharmacology, vol. 47, no. 3, pp. 286–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Takigawa and A. M. C. Brown, “Wnt signaling in liver cancer,” Current Drug Targets, vol. 9, no. 11, pp. 1013–1024, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Bhatia, R. J. Thoppil, A. Mandal, K. A. Samtani, A. S. Darvesh, and A. Bishayee, “Pomegranate bioactive constituents suppress cell proliferation and induce apoptosis in an experimental model of hepatocellular carcinoma: role of Wnt/β -catenin signaling pathway,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 371813, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Afaq, A. Malik, D. Syed, D. Maes, M. S. Matsui, and H. Mukhtar, “Pomegranate fruit extract modulates UV-B-mediated phosphorylation of mitogen-activated protein kinases and activation of nuclear factor kappa B in normal human epidermal keratinocytes,” Photochemistry and Photobiology, vol. 81, no. 1, pp. 38–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Lisbeth, G. Noratto, L. Hingorani, S. T. Talcott, and S. U. Mertens-Talcott, “Protective effects of standardized pomegranate (Punica granatum L.) polyphenolic extract in ultraviolet-irradiated human skin fibroblasts,” Journal of Agricultural and Food Chemistry, vol. 56, no. 18, pp. 8434–8441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. D. N. Syed, A. Malik, N. Hadi, S. Sarfaraz, F. Afaq, and H. Mukhtar, “Photochemopreventive effect of pomegranate fruit extract on UVA-mediated activation of cellular pathways in normal human epidermal keratinocytes,” Photochemistry and Photobiology, vol. 82, no. 2, pp. 398–405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Afaq, N. Khan, D. N. Syed, and H. Mukhtar, “Oral feeding of pomegranate fruit extract inhibits early biomarkers of UVB radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis,” Photochemistry and Photobiology, vol. 86, no. 6, pp. 1318–1326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Afaq, M. Saleem, C. G. Krueger, J. D. Reed, and H. Mukhtar, “Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-κB pathways and inhibits skin tumorigenesis in CD-1 mice,” International Journal of Cancer, vol. 113, no. 3, pp. 423–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. J. George, M. Singh, A. K. Srivastava, K. Bhui, and Y. Shukla, “Synergistic growth inhibition of mouse skin tumors by pomegranate fruit extract and diallyl sulfide: evidence for inhibition of activated MAPKs/NF-κB and reduced cell proliferation,” Food and Chemical Toxicology, vol. 49, no. 7, pp. 1511–1520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. L. S. Adams, Y. Zhang, N. P. Seeram, D. Heber, and S. Chen, “Pomegranate ellagitannin-derived compounds exhibit antiproferative and antiaromatase activity in breast cancer cells In vitro,” Cancer Prevention Research, vol. 3, no. 1, pp. 108–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Larrosa, A. González-Sarrías, M. T. García-Conesa, F. A. Tomás-Barberán, and J. C. Espín, “Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities,” Journal of Agricultural and Food Chemistry, vol. 54, no. 5, pp. 1611–1620, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. N. D. Kim, R. Mehta, W. Yu et al., “Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer,” Breast Cancer Research and Treatment, vol. 71, no. 3, pp. 203–217, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. D. A. Van Elswijk, U. P. Schobel, E. P. Lansky, H. Irth, and J. Van Der Greef, “Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry,” Phytochemistry, vol. 65, no. 2, pp. 233–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. K.-C. Jeng, C.-S. Chen, Y.-P. Fang, R. C.-W. Hou, and Y.-S. Chen, “Effect of microbial fermentation on content of statin, GABA, and polyphenols in Pu-erh tea,” Journal of Agricultural and Food Chemistry, vol. 55, no. 21, pp. 8787–8792, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Sato, M. Kohno, H. Hamano, and Y. Niwano, “Increased anti-oxidative potency of garlic by spontaneous short-term fermentation,” Plant Foods for Human Nutrition, vol. 61, no. 4, pp. 157–160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Dikmen, N. Ozturk, and Y. Ozturk, “The antioxidant potency of Punica granatum L. fruit peel reduces cell proliferation and induces apoptosis on breast cancer,” Journal of Medicinal Food, vol. 14, no. 12, pp. 1638–1646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. L. Jeune, J. Kumi-Diaka, and J. Brown, “Anticancer activities of pomegranate extracts and genistein in human breast cancer cells,” Journal of Medicinal Food, vol. 8, no. 4, pp. 469–475, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Sakamoto, H. Horiguchi, E. Oguma, and F. Kayama, “Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells,” Journal of Nutritional Biochemistry, vol. 21, no. 9, pp. 856–864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Banerjee, S. Kambhampati, S. K. Banerjee, and I. Haque, “Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells,” Journal of Cell Communication and Signaling, vol. 5, no. 4, pp. 317–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. A. B. Shirode, P. Kovvuru, S. V. Chittur, S. M. Henning, D. Heber, and R. Reliene, “Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks,” Molecular Carcinogenesis, vol. 53, no. 6, pp. 458–470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Murakawa, E. Sonoda, L. J. Barber et al., “Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells,” Cancer Research, vol. 67, no. 18, pp. 8536–8543, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Qiao, M. Kerr, B. Groselj et al., “Imatinib radiosensitizes bladder cancer by targeting homologous recombination,” Cancer Research, vol. 73, no. 5, pp. 1611–1620, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. B. Ladd, J. J. Ackroyd, J. K. Hicks, C. E. Canman, S. A. Flanagan, and D. S. Shewach, “Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity,” DNA Repair, vol. 12, no. 12, pp. 1114–1121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Toi, H. Bando, C. Ramachandran et al., “Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo,” Angiogenesis, vol. 6, no. 2, pp. 121–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. C. J. Malemud, “Matrix metalloproteinases (MMPs) in health and disease: an overview,” Frontiers in Bioscience, vol. 11, no. 2, pp. 1696–1701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. C. M. Overall and C. López-Otín, “Strategies for MMP inhibition in cancer: innovations for the post-trial era,” Nature Reviews Cancer, vol. 2, no. 9, pp. 657–672, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. I. Stamenkovic, “Matrix metalloproteinases in tumor invasion and metastasis,” Seminars in Cancer Biology, vol. 10, no. 6, pp. 415–433, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, “Matrix metalloproteinases: Biologic activity and clinical implications,” Journal of Clinical Oncology, vol. 18, no. 5, pp. 1135–1149, 2000. View at Google Scholar · View at Scopus
  71. S. Ahmed, N. Wang, B. B. Hafeez, V. K. Cheruvu, and T. M. Haqqi, “Punica granatum L. extracts inhibits IL-1β-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-κB in human chondrocytes in vitro,” Journal of Nutrition, vol. 135, no. 9, pp. 2096–2102, 2005. View at Google Scholar · View at Scopus
  72. K. S. Mix, J. A. Mengshol, U. Benbow, M. P. Vincenti, M. B. Sporn, and C. E. Brinckerhoff, “A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines,” Arthritis & Rheumatology, vol. 44, no. 5, pp. 1096–1104, 2001. View at Google Scholar
  73. F. Afaq, M. A. Zaid, N. Khan, M. Dreher, and H. Mukhtar, “Protective effect of pomegranate-derived products on UVB-mediated damage in human reconstituted skin,” Experimental Dermatology, vol. 18, no. 6, pp. 553–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Sreeja, T. R. Santhosh Kumar, B. S. Lakshmi, and S. Sreeja, “Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation,” Journal of Nutritional Biochemistry, vol. 23, no. 7, pp. 725–732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. K. A. Klein, R. E. Reiter, J. Redula et al., “Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice,” Nature Medicine, vol. 3, no. 4, pp. 402–408, 1997. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Y. Hong, N. P. Seeram, and D. Heber, “Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor,” Journal of Nutritional Biochemistry, vol. 19, no. 12, pp. 848–855, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. D. S. Ming, S. Pham, S. Deb et al., “Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 143, pp. 19–28, 2014. View at Google Scholar
  79. M. Albrecht, W. Jiang, J. Kumi-Diaka et al., “Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells,” Journal of Medicinal Food, vol. 7, no. 3, pp. 274–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Vermeulen, D. R. Van Bockstaele, and Z. N. Berneman, “The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer,” Cell Proliferation, vol. 36, no. 3, pp. 131–149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Malik, F. Afaq, S. Sarfaraz, V. M. Adhami, D. N. Syed, and H. Mukhtar, “Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 41, pp. 14813–14818, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Wang, A. Alcon, H. Yuan, J. Ho, Q.-J. Li, and M. Martins-Green, “Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells,” Integrative Biology, vol. 3, no. 7, pp. 742–754, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Wang, S. Zhang, S. Iqbal et al., “Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy,” The Prostate, vol. 74, no. 5, pp. 497–508, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Fukuda and L. M. Pelus, “Survivin, a cancer target with an emerging role in normal adult tissues,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1087–1098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. M. B. Rettig, D. Heber, J. An et al., “Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism,” Molecular Cancer Therapeutics, vol. 7, no. 9, pp. 2662–2671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Domingo-Domenech, B. Mellado, B. Ferrer et al., “Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse,” British Journal of Cancer, vol. 93, no. 11, pp. 1285–1294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. V. Fradet, L. Lessard, L. R. Bégin, P. Karakiewicz, A.-M. Mes Masson, and F. Saad, “Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer,” Clinical Cancer Research, vol. 10, no. 24, pp. 8460–8464, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. V. M. Adhami, I. A. Siddiqui, D. N. Syed, R. K. Lall, and H. Mukhtar, “Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model,” Carcinogenesis, vol. 33, no. 3, pp. 644–651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Hay, “The Akt-mTOR tango and its relevance to cancer,” Cancer Cell, vol. 8, no. 3, pp. 179–183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. S. M. Firth and R. C. Baxter, “Cellular actions of the insulin-like growth factor binding proteins,” Endocrine Reviews, vol. 23, no. 6, pp. 824–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Koyama, L. J. Cobb, H. H. Mehta et al., “Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis,” Growth Hormone and IGF Research, vol. 20, no. 1, pp. 55–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Vicinanza, Y. Zhang, S. M. Henning, and D. Heber, “Pomegranate juice metabolites, ellagic acid and urolithin a, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 247504, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. M. R. Sartippour, N. P. Seeram, J. Y. Rao et al., “Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo,” International Journal of Oncology, vol. 32, no. 2, pp. 475–480, 2008. View at Google Scholar · View at Scopus
  94. J. R. Jackson, M. P. Seed, C. H. Kircher, D. A. Willoughby, and J. D. Winkler, “The codependence of angiogenesis and chronic inflammation,” The FASEB Journal, vol. 11, no. 6, pp. 457–465, 1997. View at Google Scholar · View at Scopus
  95. B. B. Aggarwal and S. Shishodia, “Molecular targets of dietary agents for prevention and therapy of cancer,” Biochemical Pharmacology, vol. 71, no. 10, pp. 1397–1421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. S.-T. Lee, Y.-L. Wu, L.-H. Chien, S.-T. Chen, Y.-K. Tzeng, and T.-F. Wu, “Proteomic exploration of the impacts of pomegranate fruit juice on the global gene expression of prostate cancer cell,” Proteomics, vol. 12, no. 21, pp. 3251–3262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. L. Labrecque, S. Lamy, A. Chapus et al., “Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound,” Carcinogenesis, vol. 26, no. 4, pp. 821–826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. E. P. Lansky, W. Jiang, H. Mo et al., “Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions,” Investigational New Drugs, vol. 23, no. 1, pp. 11–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. K. V. Honn, R. S. Bockman, and L. J. Marnett, “Prostaglandins and cancer: a review of tumor initiation through tumor metastasis,” Prostaglandins, vol. 21, no. 5, pp. 833–864, 1981. View at Google Scholar · View at Scopus
  100. H. Sheng, J. Shao, M. K. Washington, and R. N. DuBois, “Prostaglandin E2 increases growth and motility of colorectal carcinoma cells,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 18075–18081, 2001. View at Publisher · View at Google Scholar · View at Scopus
  101. A. A. Chaudry, K. W. J. Wahle, S. McClinton, and L. E. F. Moffat, “Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors,” International Journal of Cancer, vol. 57, no. 2, pp. 176–180, 1994. View at Publisher · View at Google Scholar · View at Scopus
  102. E. P. Lansky, G. Harrison, P. Froom, and W. G. Jiang, “Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel,” Investigational New Drugs, vol. 23, no. 2, pp. 121–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Seton-Rogers, “Metastasis: multitasking hyaluronic acid,” Nature Reviews Cancer, vol. 12, no. 4, p. 228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. E. A. Turley, P. W. Noble, and L. Y. W. Bourguignon, “Signaling properties of hyaluronan receptors,” Journal of Biological Chemistry, vol. 277, no. 7, pp. 4589–4592, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Wang, J. Ho, C. Glackin, and M. Martins-Green, “Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis,” Translational Oncology, vol. 5, no. 5, pp. 344–355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. A. F. Chambers, A. C. Groom, and I. C. MacDonald, “Dissemination and growth of cancer cells in metastatic sites,” Nature Reviews Cancer, vol. 2, no. 8, pp. 563–572, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. B. A. Teicher and S. P. Fricker, “CXCL12 (SDF-1)/CXCR4 pathway in cancer,” Clinical Cancer Research, vol. 16, no. 11, pp. 2927–2931, 2010. View at Google Scholar
  108. L. Wang, W. Li, M. Lin et al., “Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis,” Carcinogenesis, vol. 35, no. 10, pp. 2321–2330, 2014. View at Publisher · View at Google Scholar
  109. A. Rocha, L. Wang, M. Penichet, and M. Martins-Green, “Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer,” Breast Cancer Research and Treatment, vol. 136, no. 3, pp. 647–658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. S. J. Freedland, M. Carducci, N. Kroeger et al., “A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy,” Cancer Prevention Research, vol. 6, no. 10, pp. 1120–1127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. A. González-Sarrías, J. A. Giménez-Bastida, M. T. García-Conesa et al., “Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice,” Molecular Nutrition and Food Research, vol. 54, no. 3, pp. 311–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Khan, N. Hadi, F. Afaq, D. N. Syed, M.-H. Kweon, and H. Mukhtar, “Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice,” Carcinogenesis, vol. 28, no. 1, pp. 163–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Khan, F. Afaq, M.-H. Kweon, K. Kim, and H. Mukhtar, “Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice,” Cancer Research, vol. 67, no. 7, pp. 3475–3482, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. T. M. Yeung, S. C. Gandhi, J. L. Wilding, R. Muschel, and W. F. Bodmer, “Cancer stem cells from colorectal cancer-derived cell lines,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 8, pp. 3722–3727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. S. G. Kasimsetty, D. Blalonska, M. K. Reddy, G. Ma, S. I. Khan, and D. Ferreira, “Colon cancer chemopreventive activities of pomegranate ellagitannins and Urolithins,” Journal of Agricultural and Food Chemistry, vol. 58, no. 4, pp. 2180–2187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. H. Dahlawi, N. Jordan-Mahy, M. R. Clench, and C. L. Le Maitre, “Bioactive actions of pomegranate fruit extracts on leukemia cell lines in vitro hold promise for new therapeutic agents for leukemia,” Nutrition and Cancer, vol. 64, no. 1, pp. 100–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Bellido and P. A. W. Te Boekhorst, “JAK2 inhibition: reviewing a new therapeutical option in myeloproliferative neoplasms,” Advances in Hematology, vol. 2012, Article ID 535709, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. A. J. Marks, M. S. Cooper, R. J. Anderson et al., “Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide,” Cancer Research, vol. 65, no. 6, pp. 2373–2377, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Fimognari, E. Turrini, P. Sestili et al., “Antileukemic activity of sulforaphane in primary blasts from patients affected by myelo- and lympho-proliferative disorders and in hypoxic conditions,” PLoS ONE, vol. 9, no. 7, Article ID e101991, 2014. View at Google Scholar
  120. A. Renneville, C. Roumier, V. Biggio et al., “Cooperating gene mutations in acute myeloid leukemia: a review of the literature,” Leukemia, vol. 22, no. 5, pp. 915–931, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. H. Dahlawi, N. Jordan-Mahy, M. Clench, G. J. McDougall, and C. L. Maitre, “Polyphenols are responsible for the proapoptotic properties of pomegranate juice on leukemia cell lines,” Food Science & Nutrition, vol. 1, no. 2, pp. 196–208, 2013. View at Publisher · View at Google Scholar
  122. Y. Hagiwara, T. Kasukabe, Y. Kaneko, N. Niitsu, and J. Okabe-Kado, “Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells,” International Journal of Hematology, vol. 92, no. 1, pp. 136–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Kawaii and E. P. Lansky, “Differentiation-promoting activity of pomegranate (Punica granatum) fruit extracts in HL-60 human promyelocytic leukemia cells,” Journal of Medicinal Food, vol. 7, no. 1, pp. 13–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. P. Fenaux, C. Chomienne, and L. Degos, “All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia,” Seminars in Hematology, vol. 38, no. 1, pp. 13–25, 2001. View at Publisher · View at Google Scholar · View at Scopus
  125. Z. Li, S. S. Percival, S. Bonard, and L. Gu, “Fabrication of nanoparticles using partially purified pomegranate ellagitannins and gelatin and their apoptotic effects,” Molecular Nutrition and Food Research, vol. 55, no. 7, pp. 1096–1103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. K. W. Powers, S. C. Brown, V. B. Krishna, S. C. Wasdo, B. M. Moudgil, and S. M. Roberts, “Research strategies for safety evaluation of nanomaterials. Part VI. characterization of nanoscale particles for toxicological evaluation,” Toxicological Sciences, vol. 90, no. 2, pp. 296–303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. S.-T. Lee, M.-H. Lu, L.-H. Chien, T.-F. Wu, L.-C. Huang, and G.-I. Liao, “Suppression of urinary bladder urothelial carcinoma cell by the ethanol extract of pomegranate fruit through cell cycle arrest and apoptosis,” BMC Complementary and Alternative Medicine, vol. 13, article 364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. S. G. Wang, M. H. Huang, J. H. Li, F. I. Lai, H. M. Lee, and Y. N. Hsu, “Punicalagin induces apoptotic and autophagic cell death in human U87MG glioma cells,” Acta Pharmacologica Sinica, vol. 34, no. 11, pp. 1411–1419, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. A. J. Pantuck, J. T. Leppert, N. Zomorodian et al., “Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer,” Clinical Cancer Research, vol. 12, no. 13, pp. 4018–4026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. C. J. Paller, X. Ye, P. J. Wozniak et al., “A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 16, no. 1, pp. 50–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. F. Stenner-Liewen, H. Liewen, R. Cathomas, C. Renner, U. Petrausch, and T. Sulser, “Daily pomegranate intake has no impact on PSA levels in patients with advanced prostate cancer—results of a phase IIb randomized controlled trial,” Journal of Cancer, vol. 4, no. 7, pp. 597–605, 2013. View at Google Scholar
  132. S. Chrubasik-Hausmann, C. Vlachojannis, and B. Zimmermann, “Pomegranate juice and prostate cancer: importance of the characterisation of the active principle,” Phytotherapy Research, vol. 28, no. 11, pp. 1676–1678, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. C. Manach and J. L. Donovan, “Pharmacokinetics and metabolism of dietary flavonoids in humans,” Free Radical Research, vol. 38, no. 8, pp. 771–785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. N. P. Seeram, Y. Zhang, R. McKeever et al., “Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects,” Journal of Medicinal Food, vol. 11, no. 2, pp. 390–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. N. P. Seeram, S. M. Henning, Y. Zhang, M. Suchard, Z. Li, and D. Heber, “Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours,” Journal of Nutrition, vol. 136, no. 10, pp. 2481–2485, 2006. View at Google Scholar · View at Scopus
  136. S. J. Klempner and G. Bubley, “Complementary and alternative medicines in prostate cancer: from bench to bedside?” Oncologist, vol. 17, no. 6, pp. 830–837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. C. Patel, P. Dadhaniya, L. Hingorani, and M. G. Soni, “Safety assessment of pomegranate fruit extract: acute and subchronic toxicity studies,” Food and Chemical Toxicology, vol. 46, no. 8, pp. 2728–2735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. D. Heber, N. P. Seeram, H. Wyatt et al., “Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size,” Journal of Agricultural and Food Chemistry, vol. 55, no. 24, pp. 10050–10054, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Aviram, M. Rosenblat, D. Gaitini et al., “Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation,” Clinical Nutrition, vol. 23, no. 3, pp. 423–433, 2004. View at Publisher · View at Google Scholar
  140. C. C. Lin, Y. F. Hsu, T. C. Lin, and H. Y. Hsu, “Antioxidant and hepatoprotective effects of punicalagin and punicalin on acetaminophen-induced liver damage in rats,” Phytotherapy Research, vol. 15, no. 3, pp. 206–212, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. B. Cerdá, J. J. Cerón, F. A. Tomás-Barberán, and J. C. Espín, “Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic,” Journal of Agricultural and Food Chemistry, vol. 51, no. 11, pp. 3493–3501, 2003. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Azorín-Ortuño, C. Urbán, J. J. Cerón et al., “Safety evaluation of an oak-flavored milk powder containing ellagitannins upon oral administration in the rat,” Journal of Agricultural and Food Chemistry, vol. 56, no. 8, pp. 2857–2865, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Sánchez-Lamar, G. Fonseca, J. L. Fuentes et al., “Assessment of the genotoxic risk of Punica granatum L. (Punicaceae) whole fruit extracts,” Journal of Ethnopharmacology, vol. 115, no. 3, pp. 416–422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. European Food Safety Authority, “Compendium of botanicals that have been reported to contain toxic, addictive, psychotropic or other substances of concern,” EFSA Journal, 2009. View at Google Scholar
  145. P. C. Shukla, K. K. Singh, B. Yanagawa, H. Teoh, and S. Verma, “DNA damage repair and cardiovascular diseases,” Canadian Journal of Cardiology, vol. 26, pp. 13A–16A, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. A. O. Khan, “Genetics of primary glaucoma,” Current Opinion in Ophthalmology, vol. 22, no. 5, pp. 347–355, 2011. View at Google Scholar
  147. E. Storkebaum, A. Quaegebeur, M. Vikkula, and P. Carmeliet, “Cerebrovascular disorders: molecular insights and therapeutic opportunities,” Nature Neuroscience, vol. 14, no. 11, pp. 1390–1397, 2011. View at Publisher · View at Google Scholar · View at Scopus